JPWO2021216853A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021216853A5 JPWO2021216853A5 JP2022564250A JP2022564250A JPWO2021216853A5 JP WO2021216853 A5 JPWO2021216853 A5 JP WO2021216853A5 JP 2022564250 A JP2022564250 A JP 2022564250A JP 2022564250 A JP2022564250 A JP 2022564250A JP WO2021216853 A5 JPWO2021216853 A5 JP WO2021216853A5
- Authority
- JP
- Japan
- Prior art keywords
- polynucleotide
- rna
- dna sequence
- target rna
- sequence encoding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108091033319 polynucleotide Proteins 0.000 claims description 97
- 239000002157 polynucleotide Substances 0.000 claims description 97
- 102000040430 polynucleotide Human genes 0.000 claims description 97
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 37
- 230000008685 targeting Effects 0.000 claims description 28
- 239000013598 vector Substances 0.000 claims description 25
- 102000039471 Small Nuclear RNA Human genes 0.000 claims description 20
- 108091029842 small nuclear ribonucleic acid Proteins 0.000 claims description 20
- 108090000623 proteins and genes Proteins 0.000 claims description 11
- 102100022712 Alpha-1-antitrypsin Human genes 0.000 claims description 10
- 101000823116 Homo sapiens Alpha-1-antitrypsin Proteins 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 108010020246 Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Proteins 0.000 claims description 8
- 102100032693 Leucine-rich repeat serine/threonine-protein kinase 2 Human genes 0.000 claims description 8
- 239000002773 nucleotide Substances 0.000 claims description 8
- 125000003729 nucleotide group Chemical group 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims description 7
- 230000000295 complement effect Effects 0.000 claims description 7
- 230000035772 mutation Effects 0.000 claims description 7
- 102100027591 Copper-transporting ATPase 2 Human genes 0.000 claims description 6
- 101000936280 Homo sapiens Copper-transporting ATPase 2 Proteins 0.000 claims description 6
- 238000010357 RNA editing Methods 0.000 claims description 6
- 230000026279 RNA modification Effects 0.000 claims description 6
- 230000007115 recruitment Effects 0.000 claims description 6
- 102100022548 Beta-hexosaminidase subunit alpha Human genes 0.000 claims description 5
- 102100029791 Double-stranded RNA-specific adenosine deaminase Human genes 0.000 claims description 5
- 101000865408 Homo sapiens Double-stranded RNA-specific adenosine deaminase Proteins 0.000 claims description 5
- KQLXBKWUVBMXEM-UHFFFAOYSA-N 2-amino-3,7-dihydropurin-6-one;7h-purin-6-amine Chemical compound NC1=NC=NC2=C1NC=N2.O=C1NC(N)=NC2=C1NC=N2 KQLXBKWUVBMXEM-UHFFFAOYSA-N 0.000 claims description 4
- 102100030755 5-aminolevulinate synthase, nonspecific, mitochondrial Human genes 0.000 claims description 4
- 102100026882 Alpha-synuclein Human genes 0.000 claims description 4
- 102100037242 Amiloride-sensitive sodium channel subunit alpha Human genes 0.000 claims description 4
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 claims description 4
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 claims description 4
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 claims description 4
- 101000843649 Homo sapiens 5-aminolevulinate synthase, nonspecific, mitochondrial Proteins 0.000 claims description 4
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 claims description 4
- 101000740448 Homo sapiens Amiloride-sensitive sodium channel subunit alpha Proteins 0.000 claims description 4
- 101001045440 Homo sapiens Beta-hexosaminidase subunit alpha Proteins 0.000 claims description 4
- 101001098868 Homo sapiens Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 claims description 4
- 101000801643 Homo sapiens Retinal-specific phospholipid-transporting ATPase ABCA4 Proteins 0.000 claims description 4
- 102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 claims description 4
- 102100033617 Retinal-specific phospholipid-transporting ATPase ABCA4 Human genes 0.000 claims description 4
- 108091026823 U7 small nuclear RNA Proteins 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 102000008371 intracellularly ATP-gated chloride channel activity proteins Human genes 0.000 claims description 4
- 102220060482 rs786201985 Human genes 0.000 claims description 4
- 102000013498 tau Proteins Human genes 0.000 claims description 4
- 108010026424 tau Proteins Proteins 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 101000584785 Homo sapiens Ras-related protein Rab-7a Proteins 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 102100030019 Ras-related protein Rab-7a Human genes 0.000 claims description 3
- 208000006289 Rett Syndrome Diseases 0.000 claims description 3
- 239000013607 AAV vector Substances 0.000 claims description 2
- 241000702423 Adeno-associated virus - 2 Species 0.000 claims description 2
- 241001634120 Adeno-associated virus - 5 Species 0.000 claims description 2
- 241001164825 Adeno-associated virus - 8 Species 0.000 claims description 2
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 claims description 2
- 102100038191 Double-stranded RNA-specific editase 1 Human genes 0.000 claims description 2
- 102000048988 Hemochromatosis Human genes 0.000 claims description 2
- 108700022944 Hemochromatosis Proteins 0.000 claims description 2
- 101150065637 Hfe gene Proteins 0.000 claims description 2
- 101000742223 Homo sapiens Double-stranded RNA-specific editase 1 Proteins 0.000 claims description 2
- 101001004953 Homo sapiens Lysosomal acid lipase/cholesteryl ester hydrolase Proteins 0.000 claims description 2
- 101000836983 Homo sapiens Secretoglobin family 1D member 1 Proteins 0.000 claims description 2
- 108091026898 Leader sequence (mRNA) Proteins 0.000 claims description 2
- 102100026001 Lysosomal acid lipase/cholesteryl ester hydrolase Human genes 0.000 claims description 2
- 208000027073 Stargardt disease Diseases 0.000 claims description 2
- 208000034799 Tauopathies Diseases 0.000 claims description 2
- 108091036066 Three prime untranslated region Proteins 0.000 claims description 2
- 108091026838 U1 spliceosomal RNA Proteins 0.000 claims description 2
- 108091023045 Untranslated Region Proteins 0.000 claims description 2
- 229960000643 adenine Drugs 0.000 claims description 2
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 claims description 2
- 229940104302 cytosine Drugs 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 201000006938 muscular dystrophy Diseases 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 102200071038 rs1800562 Human genes 0.000 claims description 2
- 238000011144 upstream manufacturing Methods 0.000 claims description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 22
- 108020005004 Guide RNA Proteins 0.000 claims 9
- 102000006479 Heterogeneous-Nuclear Ribonucleoproteins Human genes 0.000 claims 4
- 108010019372 Heterogeneous-Nuclear Ribonucleoproteins Proteins 0.000 claims 4
- 102100024108 Dystrophin Human genes 0.000 claims 2
- 101001053946 Homo sapiens Dystrophin Proteins 0.000 claims 2
- 101001053942 Saccharolobus solfataricus (strain ATCC 35092 / DSM 1617 / JCM 11322 / P2) Diphosphomevalonate decarboxylase Proteins 0.000 claims 2
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 claims 1
- 102000012758 APOBEC-1 Deaminase Human genes 0.000 claims 1
- 108010079649 APOBEC-1 Deaminase Proteins 0.000 claims 1
- 102100036664 Adenosine deaminase Human genes 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 241000702421 Dependoparvovirus Species 0.000 claims 1
- 208000029578 Muscle disease Diseases 0.000 claims 1
- 208000021642 Muscular disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000003197 catalytic effect Effects 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000014621 translational initiation Effects 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000007914 intraventricular administration Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 1
- 208000022292 Tay-Sachs disease Diseases 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001296 transplacental effect Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063013774P | 2020-04-22 | 2020-04-22 | |
| US63/013,774 | 2020-04-22 | ||
| US202063030118P | 2020-05-26 | 2020-05-26 | |
| US63/030,118 | 2020-05-26 | ||
| US202063086434P | 2020-10-01 | 2020-10-01 | |
| US63/086,434 | 2020-10-01 | ||
| US202063112486P | 2020-11-11 | 2020-11-11 | |
| US63/112,486 | 2020-11-11 | ||
| US202063119878P | 2020-12-01 | 2020-12-01 | |
| US63/119,878 | 2020-12-01 | ||
| US202163153817P | 2021-02-25 | 2021-02-25 | |
| US63/153,817 | 2021-02-25 | ||
| PCT/US2021/028618 WO2021216853A1 (en) | 2020-04-22 | 2021-04-22 | Compositions and methods using snrna components |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023523237A JP2023523237A (ja) | 2023-06-02 |
| JPWO2021216853A5 true JPWO2021216853A5 (https=) | 2024-05-02 |
| JP2023523237A5 JP2023523237A5 (https=) | 2024-05-02 |
Family
ID=78270014
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022564250A Pending JP2023523237A (ja) | 2020-04-22 | 2021-04-22 | ｓｎＲＮＡ構成要素を使用する組成物及び方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240011028A9 (https=) |
| EP (1) | EP4139453A1 (https=) |
| JP (1) | JP2023523237A (https=) |
| CN (1) | CN115777020A (https=) |
| AU (1) | AU2021261374A1 (https=) |
| CA (1) | CA3173012A1 (https=) |
| WO (1) | WO2021216853A1 (https=) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3475424A1 (en) | 2016-06-22 | 2019-05-01 | ProQR Therapeutics II B.V. | Single-stranded rna-editing oligonucleotides |
| US10941402B2 (en) | 2016-09-01 | 2021-03-09 | Proqr Therapeutics Ii B.V. | Chemically modified single-stranded RNA-editing oligonucleotides |
| GB201808146D0 (en) | 2018-05-18 | 2018-07-11 | Proqr Therapeutics Ii Bv | Stereospecific Linkages in RNA Editing Oligonucleotides |
| WO2021113270A1 (en) | 2019-12-02 | 2021-06-10 | Shape Therapeutics Inc. | Therapeutic editing |
| MX2022006991A (es) * | 2019-12-09 | 2022-08-25 | Astellas Pharma Inc | Arn guía antisentido con región funcional añadida para editar arn blanco. |
| WO2022103852A1 (en) * | 2020-11-11 | 2022-05-19 | Shape Therapeutics Inc. | Rna-editing compositions and methods of use |
| AU2022337146A1 (en) | 2021-09-03 | 2024-03-14 | Tacit Therapeutics, Inc. | Rna editing via recruitment of spliceosome components |
| US20250084408A1 (en) * | 2021-10-27 | 2025-03-13 | Shape Therapeutics Inc. | Engineered rnas |
| EP4441219A2 (en) * | 2021-12-01 | 2024-10-09 | Shape Therapeutics Inc. | Engineered guide rnas and polynucleotides for rna editing targeting lrrk2 |
| US20250154504A1 (en) | 2022-02-14 | 2025-05-15 | Proqr Therapeutics Ii B.V. | Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia |
| JP2025507958A (ja) | 2022-03-04 | 2025-03-21 | ロックアネイビオ， インコーポレイテッド | 操作された核内低分子ＲＮＡ（ｓｎＲＮＡ）を含む組成物および方法 |
| WO2023183825A2 (en) * | 2022-03-21 | 2023-09-28 | Ptc Therapeutics Gt, Inc. | Gene therapy of ush2a-associated diseases |
| GB202208387D0 (en) * | 2022-06-08 | 2022-07-20 | Ucl Business Ltd | Modified U7 snRNA construct |
| WO2024013360A1 (en) | 2022-07-15 | 2024-01-18 | Proqr Therapeutics Ii B.V. | Chemically modified oligonucleotides for adar-mediated rna editing |
| EP4555086A1 (en) | 2022-07-15 | 2025-05-21 | ProQR Therapeutics II B.V. | Oligonucleotides for adar-mediated rna editing and use thereof |
| CN120112640A (zh) * | 2022-08-24 | 2025-06-06 | 塑造治疗公司 | 用于提高rna有效载荷转录的工程化构建体 |
| CN120129747A (zh) * | 2022-10-11 | 2025-06-10 | 广州瑞风生物科技有限公司 | snRNA核酸分子及其应用 |
| WO2024081411A1 (en) * | 2022-10-13 | 2024-04-18 | Shape Therapeutics Inc. | Engineered constructs for enhanced stability or localization of rna payloads |
| AU2023364059A1 (en) * | 2022-10-18 | 2025-05-08 | Regeneron Pharmaceuticals, Inc. | Compositions and methods comprising programmable snrnas for rna editing |
| GB202215614D0 (en) | 2022-10-21 | 2022-12-07 | Proqr Therapeutics Ii Bv | Heteroduplex rna editing oligonucleotide complexes |
| AR131145A1 (es) | 2022-11-24 | 2025-02-19 | Proqr Therapeutics Ii Bv | Oligonucleótidos antisentido para el tratamiento de hemocromatosis hfe hereditaria |
| GB202218090D0 (en) | 2022-12-01 | 2023-01-18 | Proqr Therapeutics Ii Bv | Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency |
| CA3276262A1 (en) | 2022-12-09 | 2024-06-13 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of cardiovascular disease |
| WO2024137991A2 (en) * | 2022-12-23 | 2024-06-27 | Shape Therapeutics Inc. | Engineered guide rnas and polynucleotides |
| JP2026504808A (ja) * | 2023-01-18 | 2026-02-10 | アプター バイオ，インク． | 神経変性疾患の処置のためのポリヌクレオチド組成物および方法 |
| EP4652278A1 (en) * | 2023-01-18 | 2025-11-26 | Aptah Bio, Inc. | Polynucleotide compositions and methods for treatment of cancer |
| GB202300865D0 (en) | 2023-01-20 | 2023-03-08 | Proqr Therapeutics Ii Bv | Delivery of oligonucleotides |
| EP4669753A1 (en) | 2023-02-20 | 2025-12-31 | ProQR Therapeutics II B.V. | Antisense oligonucleotides for the treatment of atherosclerotic cardiovascular disease |
| GB202304363D0 (en) | 2023-03-24 | 2023-05-10 | Proqr Therapeutics Ii Bv | Chemically modified antisense oligonucleotides for use in RNA editing |
| WO2024206175A1 (en) | 2023-03-24 | 2024-10-03 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of neurological disorders |
| AU2024246572A1 (en) | 2023-03-27 | 2025-10-30 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of liver disease |
| WO2024226860A2 (en) * | 2023-04-26 | 2024-10-31 | Shape Therapeutics Inc. | Small nuclear rna processing hairpins for small rna payloads |
| EP4713450A1 (en) * | 2023-05-15 | 2026-03-25 | Shape Therapeutics Inc. | Engineered constructs with cassette arrangements for increased transcription of rna payloads |
| WO2024256620A1 (en) | 2023-06-16 | 2024-12-19 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of neurodegenerative disease |
| WO2025007937A1 (zh) * | 2023-07-04 | 2025-01-09 | 广州瑞风生物科技有限公司 | 靶向USH2A pre-mRNA假外显子PE40的snRNA及其应用 |
| WO2025051946A1 (en) | 2023-09-07 | 2025-03-13 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of metabolic disorders |
| WO2025080844A1 (en) * | 2023-10-11 | 2025-04-17 | Emugen Therapeutics Llc | Methods and compositions for altering mecp2 expression |
| WO2025104239A1 (en) | 2023-11-16 | 2025-05-22 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of classic galactosemia |
| WO2025126158A2 (en) * | 2023-12-15 | 2025-06-19 | Regeneron Pharmaceuticals, Inc. | Compositions and methods comprising small nuclear rna (snrna) targeting sod1 |
| WO2025132708A1 (en) | 2023-12-20 | 2025-06-26 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of huntington's disease |
| WO2025190385A1 (zh) * | 2024-03-14 | 2025-09-18 | 上海拓界生物医药科技有限公司 | 靶向LRRK2的RNAi剂及其医药用途 |
| GB202404661D0 (en) | 2024-04-02 | 2024-05-15 | Proqr Therapeutics Ii Bv | Antisense oligoncleotides for the treatment of liver disease |
| WO2025211949A1 (ko) * | 2024-04-05 | 2025-10-09 | 재단법인대구경북과학기술원 | ＳｅｒｐｉｎＡ１ｅ 단백질을 유효성분으로 포함하는 기억력, 인지기능 개선용 또는 뇌신경질환의 예방 또는 치료용 조성물 |
| WO2025224230A1 (en) | 2024-04-25 | 2025-10-30 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of fatty liver disease |
| GB202410081D0 (en) | 2024-07-11 | 2024-08-28 | Proqr Therapeutics Ii Bv | Antisense oligonucleotides for the treatment of cardiovascular disease |
| WO2026022136A1 (en) | 2024-07-23 | 2026-01-29 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of metabolic disorders |
| WO2026060374A2 (en) | 2024-09-16 | 2026-03-19 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of neurological disorders |
| WO2026068781A1 (en) | 2024-09-30 | 2026-04-02 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of liver disease |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030036519A1 (en) * | 1998-04-21 | 2003-02-20 | Ryszard Kole | Stable alteration of pre-mrna splicing patterns by modified rnas |
| CA2957661A1 (en) * | 2014-08-09 | 2016-02-18 | Kevin FLANIGAN | Methods and materials for activating an internal ribosome entry site in exon 5 of the dmd gene |
| US10676737B2 (en) * | 2014-12-17 | 2020-06-09 | Proqr Therapeutics Ii B.V. | Targeted RNA editing |
| DE102015012522B3 (de) * | 2015-09-26 | 2016-06-02 | Eberhard Karls Universität Tübingen | Verfahren und Substanzen zur gerichteten RNA-Editierung |
| WO2020001793A1 (en) * | 2018-06-29 | 2020-01-02 | Eberhard-Karls-Universität Tübingen | Artificial nucleic acids for rna editing |
| AU2019336793B2 (en) * | 2018-09-06 | 2024-11-21 | The Regents Of The University Of California | RNA and DNA base editing via engineered ADAR recruitment |
| EP4306116A3 (en) * | 2018-10-12 | 2024-04-17 | Peking University | Methods and compositions for editing rnas |
| EP4008784A1 (en) * | 2019-08-01 | 2022-06-08 | Astellas Pharma Inc. | Guide rna for targeted-editing with functional base sequence added thereto |
| WO2021113270A1 (en) * | 2019-12-02 | 2021-06-10 | Shape Therapeutics Inc. | Therapeutic editing |
| MX2022006991A (es) * | 2019-12-09 | 2022-08-25 | Astellas Pharma Inc | Arn guía antisentido con región funcional añadida para editar arn blanco. |
-
2021
- 2021-04-22 CN CN202180042856.3A patent/CN115777020A/zh active Pending
- 2021-04-22 AU AU2021261374A patent/AU2021261374A1/en active Pending
- 2021-04-22 JP JP2022564250A patent/JP2023523237A/ja active Pending
- 2021-04-22 EP EP21726256.7A patent/EP4139453A1/en active Pending
- 2021-04-22 CA CA3173012A patent/CA3173012A1/en active Pending
- 2021-04-22 WO PCT/US2021/028618 patent/WO2021216853A1/en not_active Ceased
- 2021-04-22 US US17/920,065 patent/US20240011028A9/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2021216853A5 (https=) | ||
| US20230203483A1 (en) | Compositions and Methods Using SNRNA Components | |
| US11920132B2 (en) | Oligonucleotide therapy for Leber congenital amaurosis | |
| ES2959815T3 (es) | Edición génica selectiva de alelo y usos de la misma | |
| JP2024500279A (ja) | Ｒｎａ編集組成物及び使用方法 | |
| Murlidharan et al. | CNS-restricted transduction and CRISPR/Cas9-mediated gene deletion with an engineered AAV vector | |
| JP6752151B2 (ja) | 遺伝子サイレンシングにおいて低下したｏｆｆ−ｔａｒｇｅｔ効果を有するｕｎａオリゴマー | |
| JP2021502060A5 (https=) | ||
| JP7188804B2 (ja) | ジストロフィー型表皮水疱症を処置するためのアンチセンスオリゴヌクレオチド | |
| JP2021500049A5 (https=) | ||
| WO2017050836A1 (en) | Antisense oligonucleotides and uses thereof | |
| JP2019515663A5 (https=) | ||
| RU2018137677A (ru) | Модифицированная промоторная система u6 для тканеспецифической экспрессии | |
| US20250084408A1 (en) | Engineered rnas | |
| JP2020527167A5 (https=) | ||
| JPWO2023077013A5 (https=) | ||
| WO2024235283A1 (en) | Method of modulating rna splicing | |
| US20210054371A1 (en) | Conjugates of Guide RNA-Cas Protein Complex | |
| CN120129747A (zh) | snRNA核酸分子及其应用 | |
| US20250027115A1 (en) | Conjugates of guide RNA-Cas protein complex for genome and epigenome editing | |
| US20240307514A1 (en) | Modulation of acmsd protein expression | |
| JPWO2021076941A5 (https=) | ||
| Alberti et al. | From molecular convergence to clinical divergence: Comparative pathogenic mechanisms and therapeutic trajectories in C9orf72-ALS/FTD and myotonic dystrophy | |
| RU2024123023A (ru) | Олигонуклеотидные модуляторы, активирующие экспрессию утрофина | |
| CA2999192C (en) | Antisense oligonucleotides hybridizing with a key element of the polyadenylation region of a dux4 pre-mrna and uses thereof |